Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals develops RNA-targeted therapeutics for various indications. They offer existing treatments for spinal muscular atrophy (SMA), hereditary transthyretin amyloidosis, and familial chylomicronemia syndrome. The company also has multiple medicines in phase 3 studies, including treatments for ATTR, hereditary angioedema, amyotrophic lateral sclerosis, cardiovascular disease, and hepatitis B virus.
Overview
Strengths
- Paying down debt: long-term debt fell by 3.2 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 6.2% in 6 of the last 7 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 5 of the last 7 years.
- Unstable profitability: operating margin ranged from -70% to 33% over the last 7 years, with operating losses in 6 of them.
Key Financial Data